{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:43:43Z","timestamp":1786178623229,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00894-026-06857-7","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:10:04Z","timestamp":1784358604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Network toxicology-driven repurposing of metformin for hepatocellular carcinoma: insights from molecular docking and dynamics simulations"],"prefix":"10.1007","volume":"32","author":[{"given":"Gong","family":"Wenqian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Wuguang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Kaifeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zuguo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"2","key":"6857_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020149","volume":"12","author":"D Galun","year":"2022","unstructured":"Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D (2022) Precision medicine for hepatocellular carcinoma: clinical perspective. J Pers Med 12(2):149","journal-title":"J Pers Med"},{"issue":"9","key":"6857_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092506","volume":"15","author":"A Lazzaro","year":"2023","unstructured":"Lazzaro A, Hartshorn KL (2023) A comprehensive narrative review on the history, current landscape, and future directions of hepatocellular carcinoma (HCC) systemic therapy. Cancers (Basel) 15(9):2506","journal-title":"Cancers (Basel)"},{"issue":"11","key":"6857_CR3","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.3390\/ijms22116139","volume":"22","author":"M Xing","year":"2021","unstructured":"Xing M, Wang X, Kirken RA, He L, Zhang JY (2021) Immunodiagnostic biomarkers for hepatocellular carcinoma (HCC): the first step in detection and treatment. Int J Mol Sci 22(11):6139","journal-title":"Int J Mol Sci"},{"issue":"14","key":"6857_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411471","volume":"24","author":"M Kotsari","year":"2023","unstructured":"Kotsari M, Dimopoulou V, Koskinas J, Armakolas A (2023) Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci 24(14):11471","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6857_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5582\/bst.2021.01094","volume":"15","author":"Y Sugawara","year":"2021","unstructured":"Sugawara Y, Hibi T (2021) Surgical treatment of hepatocellular carcinoma. Biosci Trends 15(3):138\u2013141","journal-title":"Biosci Trends"},{"issue":"6","key":"6857_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault J-C, Neumann U, Ricke J (2021) Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 32(6):801\u2013805","journal-title":"Ann Oncol"},{"key":"6857_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2024.08.006","author":"B Yu","year":"2024","unstructured":"Yu B, Ma W (2024) Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis. Cytokine Growth Factor Rev. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.08.006","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"6857_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112798","volume":"14","author":"E Chakraborty","year":"2022","unstructured":"Chakraborty E, Sarkar D (2022) Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel) 14(11):2798","journal-title":"Cancers (Basel)"},{"issue":"18","key":"6857_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184383","volume":"14","author":"T Kimura","year":"2022","unstructured":"Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S (2022) The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC). Cancers (Basel) 14(18):4383","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6857_CR10","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v4i3.968","volume":"4","author":"S Soraya","year":"2024","unstructured":"Soraya S, Arfianti A, Adikusuma W, Irham LM, Hamidy MY, Winarto W, Rangkuti IF, Darmawi D (2024) Unveiling the impacts of metformin on hepatocellular carcinoma: a bioinformatic exploration in cell lines. Narra J 4(3):e968","journal-title":"Narra J"},{"key":"6857_CR11","doi-asserted-by":"publisher","unstructured":"Ducreux M, Zhu AX, Cheng AL, Galle PR, Ikeda M, Nicholas A, Verret W, Li L, Gaillard VE, Lencioni R, Finn RS (2021) Abstract 4071: IMbrave150: exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo)+ bevacizumab (bev) versus sorafenib (sor).\u00a0J Clin Oncol\u00a039(15_suppl):4071. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4071","DOI":"10.1200\/JCO.2021.39.15_suppl.4071"},{"issue":"3","key":"6857_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3350\/cmh.2024.0038","volume":"30","author":"PC Tsai","year":"2024","unstructured":"Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH (2024) Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. Clin Mol Hepatol 30(3):468","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"6857_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123161","volume":"15","author":"SP Papadakos","year":"2023","unstructured":"Papadakos SP, Ferraro D, Carbone G, Frampton AE, Vennarecci G, Kykalos S, Schizas D, Theocharis S, Machairas N (2023) The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy? Cancers (Basel) 15(12):3161","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6857_CR14","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/j.jhep.2022.12.011","volume":"78","author":"H Lin","year":"2023","unstructured":"Lin H, Yiu DCY, Chin S, Liu K, Yip TCF (2023) Metformin in patients with hepatocellular carcinoma receiving immunotherapy. J Hepatol 78(5):e180\u2013e182","journal-title":"J Hepatol"},{"issue":"12","key":"6857_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123202","volume":"10","author":"D T\u00fcmen","year":"2022","unstructured":"T\u00fcmen D, Heumann P, G\u00fclow K, Demirci CN, Cosma LS, M\u00fcller M, Kandulski A (2022) Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines 10(12):3202","journal-title":"Biomedicines"},{"issue":"11","key":"6857_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2174\/1389557522666220623150717","volume":"23","author":"K Wang","year":"2023","unstructured":"Wang K, Zhang K, Zhang X, Chen D, Jiang S (2023) Recent insights of metformin on hepatocellular carcinoma (HCC). Mini Rev Med Chem 23(11):1154\u20131166","journal-title":"Mini Rev Med Chem"},{"key":"6857_CR17","doi-asserted-by":"publisher","unstructured":"Ali FE, Abdel-Reheim MA, Hassanein EH, Abd El Aziz MK, Althagafy HS, Badran KS (2024) Exploring the potential of drug repurposing for liver diseases: a comprehensive study.\u00a0Life Sci 347:122642. https:\/\/doi.org\/10.1016\/j.lfs.2024.122642","DOI":"10.1016\/j.lfs.2024.122642"},{"issue":"18","key":"6857_CR18","doi-asserted-by":"publisher","first-page":"22120","DOI":"10.18632\/aging.203464","volume":"13","author":"Z Shen","year":"2021","unstructured":"Shen Z, Zhou H, Li A, Wu T, Ji X, Guo L, Zhu X, Zhang D, He X (2021) Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (albany NY) 13(18):22120","journal-title":"Aging (albany NY)"},{"issue":"1","key":"6857_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43440-024-00662-w","volume":"77","author":"YA Abdelrady","year":"2025","unstructured":"Abdelrady YA, Thabet HS, Sayed AM (2025) The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing. Pharmacol Rep 77(1):1\u201320","journal-title":"Pharmacol Rep"},{"issue":"2","key":"6857_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101781","volume":"46","author":"Q Li","year":"2022","unstructured":"Li Q, Xu H, Sui C, Zhang H (2022) Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 46(2):101781","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"6857_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/ddc2020013","volume":"2","author":"RJ Mani","year":"2023","unstructured":"Mani RJ, Anand M, Agarwal K, Tiwari A, Amanur Rahman Hashmi Q, Vikram Singh T, Nongdam P, Katare DP, Potshangabam AM (2023) A systematic review of molecular pathway analysis of drugs for potential use in liver cancer treatment. Drugs and Drug Candidates 2(2):210\u2013231","journal-title":"Drugs and Drug Candidates"},{"issue":"3","key":"6857_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/fcp.12981","volume":"38","author":"EI Salim","year":"2024","unstructured":"Salim EI, Elsebakhy S, Hessien M (2024) Repurposing of atorvastatin and metformin denotes their individual and combined antiproliferative effects in non-small cell lung cancer. Fundam Clin Pharmacol 38(3):550\u2013560","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"6857_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247231","volume":"16","author":"WR Cho","year":"2021","unstructured":"Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, Lin MT, Chen KD, Chuang CH, Huang PY (2021) Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS ONE 16(3):e0247231","journal-title":"PLoS ONE"},{"key":"6857_CR24","doi-asserted-by":"publisher","unstructured":"Attia YM, Ewida H, Ahmed MS (2020) Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma. In: To KW, Cho WC (eds) Drug repurposing in cancer therapy. Elsevier, pp 213\u2013229. https:\/\/doi.org\/10.1016\/B978-0-12-819668-7.00008-7","DOI":"10.1016\/B978-0-12-819668-7.00008-7"},{"key":"6857_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep20441","volume":"6","author":"T Hart","year":"2016","unstructured":"Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L (2016) Toward repurposing metformin as a precision anti-cancer therapy using structural systems pharmacology. Sci Rep 6:20441","journal-title":"Sci Rep"},{"issue":"43","key":"6857_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031437","volume":"101","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wang X, Yan C, Li C, Zhang L, Zhang L, Liang E, Liu T, Mao J (2022) Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore) 101(43):e31437","journal-title":"Medicine (Baltimore)"},{"key":"6857_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2023.1120370","volume":"3","author":"LM Bertoline","year":"2023","unstructured":"Bertoline LM, Lima AN, Krieger JE, Teixeira SK (2023) Before and after AlphaFold2: an overview of protein structure prediction. Front Bioinform 3:1120370","journal-title":"Front Bioinform"},{"issue":"5","key":"6857_CR28","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1007\/s00210-024-03598-3","volume":"398","author":"Y Hu","year":"2025","unstructured":"Hu Y, Xiao Y (2025) Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis. Naunyn Schmiedebergs Arch Pharmacol 398(5):5693\u20135703","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"6857_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40199-024-00523-0","volume":"32","author":"M Mahfauz","year":"2024","unstructured":"Mahfauz M, Yuruker O, Kalkan R (2024) Repurposing metformin as a potential anticancer agent using in silico technique. Daru J Pharm Sci 32(2):549\u2013555","journal-title":"Daru J Pharm Sci"},{"issue":"12","key":"6857_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12032-021-01576-w","volume":"38","author":"G Nair","year":"2021","unstructured":"Nair G, Hema Sree GNS, Saraswathy GR, Marise VLP, Krishna Murthy TP (2021) Application of comprehensive bioinformatics approaches to reconnoiter crucial genes and pathways underpinning hepatocellular carcinoma: a drug repurposing endeavor. Med Oncol 38(12):145","journal-title":"Med Oncol"},{"key":"6857_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.humgen.2024.201364","author":"S Sabarathinam","year":"2025","unstructured":"Sabarathinam S, Venkatachalapathy R, Jayaraman A (2025) Metformin\u2019s modulation of gut microbiota and its implications for Non-Alcoholic Fatty Liver Disease (NAFLD): a network pharmacology and molecular dynamics study. Hum Gene. https:\/\/doi.org\/10.1016\/j.humgen.2024.201364","journal-title":"Hum Gene"},{"issue":"11","key":"6857_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/1062936X.2024.2434577","volume":"35","author":"DK Sabir","year":"2024","unstructured":"Sabir DK, Bin Jumah JA, Ancy I (2024) Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations. SAR QSAR Environ Res 35(11):1045\u20131070","journal-title":"SAR QSAR Environ Res"},{"issue":"1","key":"6857_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12906-024-04453-x","volume":"24","author":"EI Salim","year":"2024","unstructured":"Salim EI, Alabasy MM, Nashar EME, Al-Zahrani NS, Alzahrani MA, Guo Z, Beltagy DM, Shahen M (2024) Molecular interactions between metformin and D-limonene inhibit proliferation and promote apoptosis in breast and liver cancer cells. BMC Complement Med Ther 24(1):185","journal-title":"BMC Complement Med Ther"},{"key":"6857_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115531","volume":"297","author":"Q Yu","year":"2022","unstructured":"Yu Q, Chen Z, Liu M, Meng Y, Li X, Li B, Du J (2022) Exploring the potential targets of Sanshimao formula for hepatocellular carcinoma treatment by a method of network pharmacology combined with molecular biology. J Ethnopharmacol 297:115531","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"6857_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","volume":"18","author":"L Li","year":"2023","unstructured":"Li L, Yang L, Yang L, He C, He Y, Chen L, Dong Q, Zhang H, Chen S, Li P (2023) Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin Med 18(1):146","journal-title":"Chin Med"},{"issue":"1","key":"6857_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL (2024) Drug repurposing for cancer therapy. Signal Transduct Target Ther 9(1):92","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-026-06857-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:34:12Z","timestamp":1786178052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-026-06857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["6857"],"URL":"https:\/\/doi.org\/10.1007\/s00894-026-06857-7","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally to this paper and have given approval to the final version of the manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"276"}}